



Media Contact:
Jonathan Black
JDP THERAPEUTICS, INC.
Email: info@jdptherapeutics.com
www.jdptherapeutics.com

JDP Enters Development and Supply Agreement with Hospira/Pfizer

BLUE BELL, PENNSYLVANIA, March 24, 2016 – JDP Therapeutics Inc., a privately held late stage specialty pharmaceutical company, today announced that it has entered into a development, manufacture and supply agreement, for JDP-205, with Hospira Worldwide Inc. (a Pfizer company), the global market leader of injectable pharmaceutical products. Under this agreement, Hospira will be responsible for the remaining CMC activities for JDP-205’s NDA, including development and manufacture of JDP-205’s registration & Phase III clinical batches; Hospira will also be responsible for manufacture and supply of commercial quantities of JDP-205. JDP’s President and CEO Dr. Jie Du commented, “JDP is proud to announce this partnership with Hospira/Pfizer, the global pharmaceutical leader. Beyond JDP-205, we look forward to further collaboration with Hospira/Pfizer on JDP’s other injectable products via the 505b(2) regulatory pathways.”

About JDP-205

JDP-205 is a proprietary injectable product being developed for the treatment of acute allergic reactions for the hospital market. A market QUANT study surveyed 110 physicians, and revealed that 86% of responding doctors had indicated readiness to use JDP-205 in place of the current therapy when the product is approved by the FDA. A second independent market research study with in-depth clinician interviews confirmed the findings.

Acute allergic reaction is a serious condition, potentially life-threatening, and has been growing at concerning rates with very limited selections of medications for treatment. JDP-205 will offer an alternative and superior treatment to the current therapy for the first time in nearly 60 years. JDP-205 is projected to have a significant commercial opportunity with its peak annual sales in the range of ~\$300MM.

About JDP Therapeutics Inc.

JDP Therapeutics Inc. is a privately held, clinical phase III stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens the development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email info@jdptherapeutics.com

###

Safe Harbor Statement Regarding Forward-looking Statements

The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical fact, including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.